PLGA-mPEG, MW x 16K, n 2K provides a biodegradable amphiphilic block copolymer for nanoparticle formulation and controlled drug delivery research and specifically combines a 16 kDa poly(lactic-co-glycolic acid) (PLGA) block with a 2 kDa methoxy polyethylene glycol (mPEG) chain. Its PLGA-rich composition supports hydrophobic drug encapsulation, while the PEG segment contributes hydrophilic functionality and nanoparticle surface hydration.
Key Features and Benefits
- 16 kDa PLGA Block: Provides a biodegradable hydrophobic polyester segment for polymeric nanoparticle formation, drug encapsulation, and sustained-release formulation research.
- 2 kDa mPEG Block: Introduces a short hydrophilic PEG chain that specifically contributes to nanoparticle surface hydration and aqueous dispersion properties.
- Amphiphilic Structure: Combines hydrophobic PLGA and hydrophilic mPEG segments to specifically support nanoparticle formation under suitable formulation conditions.
- Biodegradable Backbone: Contains hydrolytically degradable ester bonds that enable investigations of polymer degradation, matrix erosion, and drug release behavior.
- PLGA-Rich Composition: Features a nominal 8:1 PLGA-to-mPEG molecular weight ratio, providing substantial hydrophobic content for drug encapsulation research.
- Methoxy-Terminated PEG: Incorporates a methyl ether terminus without a dedicated reactive conjugation group, supporting preparation of PEG-containing polymeric materials.
- Short Hydrophilic Segment: Enables researchers to investigate how PEG chain length influences nanoparticle hydration, surface interactions, aggregation, and colloidal stability.
- Controlled-Release Potential: Supports biodegradable polymer matrices specifically for evaluating drug diffusion, polymer hydrolysis, and sustained-release behavior.
- Formulation Versatility: Accommodates nanoprecipitation, emulsification, and solvent evaporation techniques for developing polymeric nanoparticles with different characteristics.
Applications
- Polymeric Nanoparticle Development: Supports preparation of biodegradable nanoparticles containing PLGA-rich hydrophobic domains and short hydrophilic mPEG segments.
- Hydrophobic Drug Encapsulation: Enables incorporation of compatible, poorly water-soluble compounds into biodegradable PLGA-based polymer matrices.
- Controlled Drug Release: Supports investigations of drug diffusion, polymer degradation, and matrix erosion in sustained-release formulations.
- Drug Delivery Research: Facilitates development of biodegradable polymer carriers for encapsulating and delivering compatible therapeutic research compounds.
- Nanoparticle Surface Engineering: Enables comparisons of PEG chain lengths to investigate particle hydration, surface interactions, and colloidal stability.
- Polymer Degradation Studies: Supports evaluation of PLGA hydrolysis, molecular weight reduction, and degradation-dependent drug release behavior.
- Biodegradable Biomaterials: Provides a polymer building block for developing experimental biodegradable materials and evaluating their structural and degradation properties.
- Nanoparticle Stability Studies: Facilitates characterization of particle size, aggregation, dispersion stability, and formulation performance under different conditions.
- Polymer Composition Research: Supports comparisons of PLGA-to-PEG molecular weight ratios and their effects on nanoparticle formation, drug loading, and release profiles.
Storage and Handling
- Storage: Store at −20°C in a dry, tightly sealed container, protected from moisture and excessive heat. Follow product-specific storage instructions when available, and minimize humidity exposure to reduce premature PLGA hydrolysis.
- Handling: Handle using clean, dry equipment and dissolve in a compatible solvent, such as dichloromethane, acetone, DMF, or DMSO. Confirm solubility before selecting the formulation method.
- Prepare nanoparticles through nanoprecipitation, emulsification, or solvent evaporation, depending on the desired formulation characteristics. The nominal 8:1 PLGA-to-mPEG ratio provides a substantial hydrophobic fraction with approximately 11.1% PEG by nominal block mass.
- Evaluate particle size, stability, drug loading, and release behavior using suitable analytical techniques. Avoid prolonged exposure to moisture, strong acids, and alkaline conditions. Confirm the PLGA lactide-to-glycolide ratio and polymer specifications before use.
PLGA-mPEG, MW x 16K, n 2K combines biodegradable PLGA with short-chain mPEG for polymeric nanoparticle and biomaterials research and specifically supports hydrophobic drug encapsulation, controlled-release development, polymer degradation studies, and nanoparticle characterization.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.